secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001437749-25-030631
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q3 sales fall 8% to $5.5M; 9-month sales up 7% to $20M
---------------------------------------------------------------

- Preliminary Q3 2025 product sales $5.5M vs $6.0M in Q3 2024, an 8% decrease.
- Nine-month 2025 sales $20.0M, up 7% from $18.7M; trailing twelve-month sales $27.8M, up 16%.
- Drop attributed to end of distributor restocking that boosted H1 2025; guidance warned of H2 softening.
- Re-Tain Investigational Product use started in controlled study with Michigan State; no revenue expected.
- Non-Administrative NADA for Re-Tain submitted Jan. 2025; clearance of contract manufacturer inspection remaining hurdle.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774925030631/0001437749-25-030631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774925030631/iccc20251007_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-030631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer